Literature DB >> 25001088

Association between LAPTM4B gene polymorphism and breast cancer susceptibility in an Iranian population.

Mohammad Hashemi1, Sahadi Amininia, Mahboubeh Ebrahimi, Seyed Mehdi Hashemi, Javad Yousefi, Ebrahim Eskandari-Nasab, Mohsen Taheri, Saeid Ghavami.   

Abstract

Lysosome associated protein transmembrane 4beta (LAPTM4B) contribute to the risk of numerous cancers. The present study focused on the possible association between LAPTM4B polymorphism and the risk of breast cancer (BC) in an Iranian population in southeast Iran. This case control study includes 311 BC patients and 225 healthy women. Genomic DNA was extracted from the whole blood by salting out method and LAPTM4B genotype was investigated using polymerase chain reaction. Our findings showed that LAPTM4B genotype was not associated with the risk of BC in any inheritance model tested. The minor allele frequency in case and control group was 0.297 and 0.278, respectively. The minor allele (LAPTM4B*2) was not associated with BC risk in comparison with LAPTM4B*1 allele (odds ratio 1.10, 95 % confidence intervals 0.84-1.44, p = 0.495). Moreover, LAPTM4B polymorphism was not associated with clinical and pathological characteristics in the patient group. In conclusion, the findings of our study suggested that the polymorphism of LAPTM4B gene was not associated with susceptibility to BC and clinicopathological characteristics in an Iranian population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25001088     DOI: 10.1007/s12032-014-0111-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  Biological function of a novel gene overexpressed in human hepatocellular carcinoma.

Authors:  J Liu; R Zhou; N Zhang; J Rui; C Jin
Journal:  Chin Med J (Engl)       Date:  2000-10       Impact factor: 2.628

2.  [Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer].

Authors:  Changlin Li; Qinghua Zhou; Yanping Wang; Xiaohe Chen; Xueqin Yang; Daxing Zhu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2006-04-20

3.  Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients.

Authors:  Hua Yang; Guojun Zhai; Xiaoxu Ji; Fuxia Xiong; Jing Su; Michael A McNutt
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

4.  Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer.

Authors:  Ebrahim Eskandari-Nasab; Mohammad Hashemi; Hamzeh Rezaei; Aliakbar Fazaeli; Mohammad Ali Mashhadi; Simin Sargholzaei Moghaddam; Farshid Arbabi; Mahdi Jahantigh; Mohsen Taheri
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

5.  Correlation of LAPTM4B polymorphisms with cervical carcinoma.

Authors:  Fanling Meng; Hongtao Song; Chang Luo; Mingzhu Yin; Ye Xu; Haixia Liu; Rouli Zhou; Ge Lou
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

6.  Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.

Authors:  Min Xiao; Shusheng Jia; Hongbin Wang; Jinsong Wang; Yuanxi Huang; Zhigao Li
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-06       Impact factor: 4.553

7.  hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population.

Authors:  Mohsen Omrani; Mohammad Hashemi; Ebrahim Eskandari-Nasab; Seyed-Shahaboddin Hasani; Mohammad Ali Mashhadi; Farshid Arbabi; Mohsen Taheri
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

8.  Association of LAPTM4B gene polymorphism with nasopharyngeal carcinoma susceptibility in a Chinese population.

Authors:  Bing Wang; Jianjun Xu; Rouli Zhou; Qingyun Zhang
Journal:  Med Oncol       Date:  2013-01-24       Impact factor: 3.064

9.  LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.

Authors:  Yu Yang; Hua Yang; Michael A McNutt; Fuxia Xiong; Xiu Nie; Li Li; Rouli Zhou
Journal:  Oncol Rep       Date:  2008-11       Impact factor: 3.906

10.  LAPTM4B allele *2 is associated with breast cancer susceptibility and prognosis.

Authors:  Xiaoyan Li; Xiangnan Kong; Xi Chen; Ning Zhang; Liyu Jiang; Tingting Ma; Qifeng Yang
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more
  6 in total

1.  Association between CCNE1 polymorphisms and the risk of breast cancer in a sample of southeast Iranian population.

Authors:  Shadi Amininia; Mohammad Hashemi; Mahboubeh Ebrahimi; Mohammad Ali Mashhadi; Seyed Mehdi Hashemi; Mohsen Taheri; Saeid Ghavami
Journal:  Med Oncol       Date:  2014-08-27       Impact factor: 3.064

2.  Association between LAPTM4B gene polymorphism and prostate cancer susceptibility in an Iranian population.

Authors:  Mohammad Hashemi; Maryam Rezaei; Behzad Narouie; Nasser Simforoosh; Abbas Basiri; Sayed Amir Mohsen Ziaee; Gholamreza Bahari; Mohsen Taheri
Journal:  Mol Cell Oncol       Date:  2016-04-15

Review 3.  Association of TIMP-1 and COL4A4 Gene Polymorphisms with Keratoconus in an Iranian Population.

Authors:  Davood Yari; Zohreh Ehsanbakhsh; Mohammad-Hosein Validad; Farzaneh Hasanian Langroudi
Journal:  J Ophthalmic Vis Res       Date:  2020-08-06

4.  FEN1 -69G>A and +4150G>T polymorphisms and breast cancer risk.

Authors:  Maryam Rezaei; Mohammad Hashemi; Sara Sanaei; Mohammad Ali Mashhadi; Seyed Mehdi Hashemi; Gholamreza Bahari; Mohsen Taheri
Journal:  Biomed Rep       Date:  2016-08-08

5.  Relationship between LAPTM4B Gene Polymorphism and Prognosis of Patients following Tumor Resection for Colorectal and Esophageal Cancers.

Authors:  Xiaojing Cheng; Xiuyun Tian; Xiaojiang Wu; Xiaofang Xing; Hong Du; Chunlian Zhou; Qingyun Zhang; Chunyi Hao; Xianzi Wen; Jiafu Ji
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

6.  LAPTM4B gene polymorphism augments the risk of cancer: Evidence from an updated meta-analysis.

Authors:  Mohammad Hashemi; Gholamreza Bahari; Farhad Tabasi; Jarosław Markowski; Andrzej Małecki; Saeid Ghavami; Marek J Łos
Journal:  J Cell Mol Med       Date:  2018-09-25       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.